253 related articles for article (PubMed ID: 36754451)
1. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
2. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
3. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
5. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract][Full Text] [Related]
7. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ
JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
9. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
10. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
11. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
Hecht M; Eckstein M; Rutzner S; von der Grün J; Illmer T; Klautke G; Laban S; Hautmann MG; Brunner TB; Tamaskovics B; Hinke A; Zhou JG; Frey B; Donaubauer AJ; Becker I; Semrau S; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Gostian AO; Fietkau R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078923
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.
Kuang C; Park Y; Augustin RC; Lin Y; Hartman DJ; Seigh L; Pai RK; Sun W; Bahary N; Ohr J; Rhee JC; Marks SM; Beasley HS; Shuai Y; Herman JG; Zarour HM; Chu E; Lee JJ; Krishnamurthy A
Clin Epigenetics; 2022 Jan; 14(1):3. PubMed ID: 34991708
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
Hecht M; Gostian AO; Eckstein M; Rutzner S; von der Grün J; Illmer T; Hautmann MG; Klautke G; Laban S; Brunner T; Hinke A; Becker I; Frey B; Semrau S; Geppert CI; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Fietkau R
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023982
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
17. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Monge C; Xie C; Myojin Y; Coffman-D'Annibale KL; Hrones D; Brar G; Wang S; Budhu A; Figg WD; Cam M; Finney R; Levy EB; Kleiner DE; Steinberg SM; Wang XW; Redd B; Wood BJ; Greten TF
Cancer Med; 2024 Feb; 13(3):e6912. PubMed ID: 38205877
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Fumet JD; Isambert N; Hervieu A; Zanetta S; Guion JF; Hennequin A; Rederstorff E; Bertaut A; Ghiringhelli F
ESMO Open; 2018; 3(4):e000375. PubMed ID: 29942666
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Garon EB; Spira AI; Goldberg SB; Chaft JE; Papadimitrakopoulou V; Cascone T; Antonia SJ; Brahmer JR; Camidge DR; Powderly JD; Wozniak AJ; Felip E; Wu S; Ascierto ML; Elgeioushi N; Awad MM
J Thorac Oncol; 2023 Aug; 18(8):1094-1102. PubMed ID: 37146752
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
